Zogenix delivery tech earns patent; Researchers find nanoparticles damage brain;

> Zogenix ($ZGNX) revealed that it was issued a patent on the biphasic pressure profile utilized by the company's proprietary DosePro Needle-free Delivery System. Release

> The hype around nanoparticles might not be all it's cracked up to be, according to research that saw a correlation of brain damage in rats inserted with micelles nanoparticles. A toxic positive charge on the nanoparticles' surface is reported to cause the damage. Story

> Tiny DNA pyramids, an engineered nanomedicine, might be a forthcoming defense in fighting the growing problem of antibiotic resistance. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.